The Covid-19 pandemic has accelerated the digitisation of healthcare and the adoption of virtual care models by healthcare systems in the US. The pandemic has also catalyzed a wider paradigm shift toward the consumerization of healthcare and value-based care delivery. Patients now expect a higher, more personalized and more convenient standard of care. Healthcare providers recognise the need to adopt digital tools to deliver better outcomes and take advantage of new revenue opportunities (whilst keeping costs down).
These trends have driven a new wave of innovation in at-home diagnostics, telemedicine and remote patient monitoring. And the data generated from virtual healthcare services (“real world evidence”) is being used to inform drug discovery, shorten clinical trials, and reduce the time to market. This all plays into Israel’s strengths which is rooted in a data-rich healthcare system (Sheba was one of the first Healthcare institutions to create a centralized data strategy) and a willingness to engage in POCs/trials with start-up innovation.
A research-led firm, MizMaa looks to invest in digital health technology that puts the patient at the center and gives greater access to integrated care pathways and at-home care delivery. We see opportunity in AI-enabled digital tools that are integrated into the workflow and aid decision making or reduce administrative burden. And fundamentally, we believe it is important that this technology helps close existing health inequalities, for example in Behavioral Health, Women’s Health and Elderly Care, and for traditionally underserved populations including women, people of color, rural patients and lower income families.